Overview

Using ctDNA to Determine Therapies for Lung Cancer

Status:
Not yet recruiting
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
This is a study to look at whether the presence of circulating tumour DNA (ctDNA) in the blood can help to predict whether giving adjuvant treatment after surgery can decrease the chance of the cancer coming back in people with lung cancer.
Phase:
Phase 2
Details
Lead Sponsor:
University Health Network, Toronto
Collaborator:
Bristol-Myers Squibb
Treatments:
Carboplatin
Gemcitabine
Nivolumab
Pemetrexed